Acute Cellular Rejection and the Subsequent Development of Allograft Vasculopathy After Cardiac Transplantation

被引:128
作者
Raichlin, Eugenia [1 ,2 ,3 ]
Edwards, Brooks S. [1 ,2 ]
Kremers, Walter K. [1 ,4 ]
Clavell, Alfredo L. [1 ,2 ]
Rodeheffer, Richard J. [1 ,2 ]
Frantz, Robert P. [1 ,2 ]
Pereira, Naveen L. [1 ,2 ]
Daly, Richard C. [1 ,5 ]
McGregor, Christopher G. [1 ,5 ]
Lerman, Amir [2 ,3 ]
Kushwaha, Sudhir S. [1 ,2 ]
机构
[1] Mayo Clin, William J von Liebig Transplant Ctr, Rochester, MN USA
[2] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA
[3] Mayo Clin, Ctr Coronary Physiol & Imaging, Rochester, MN USA
[4] Mayo Clin, Div Biostat, Rochester, MN USA
[5] Mayo Clin, Div Cardiovasc Surg, Rochester, MN USA
关键词
CORONARY-ARTERY-DISEASE; C-REACTIVE PROTEIN; RISK-ASSESSMENT STRATEGIES; INTRAVASCULAR ULTRASOUND; HEART-TRANSPLANTATION; INTERNATIONAL-SOCIETY; LUNG-TRANSPLANTATION; VULNERABLE PLAQUE; PRIMARY IMMUNOSUPPRESSION; MYCOPHENOLATE-MOFETIL;
D O I
10.1016/j.healun.2009.01.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cardiac allograft vasculopathy (CAV) is primarily immune-mediated. We investigated the role. of cellular rejection in CAV development. Methods: The study comprised 252 cardiac transplant recipients (mean age, 49.02 +/- 17.05 years; mean follow-up, 7.61 +/- 4.49 years). Total rejection score (TRS) based on the 2004 International Society of Heart and Lung Transplantation R grading system (OR = 0, 1R = 1, 2R = 2, 3R = 3) and any rejection score (ARS; calculated as OR = 0, 1R = 1, 2R = 1; 311 = 1, or the number of rejections of any,grade) were normalized for the total number of biopsy specimens. CAV was defined as coronary stenosis of 40% or more and/or distal pruning of secondary side branches. Thirty-two patients had undergone 3-dimensional intravascular ultrasound (IVUS) at baseline and with virtual histology (VH) IVUS at 24 months. Results: In univariate analysis, 6-month TRS (hazard ratio [HR], 1.9; 95% confidence interval [CI] 0.99-3-90, P = 0.05) and ARS (HR, 2.22; 95% CI, 1.01-4-95; p = 0.047) were associated with increased risk of CAV. In multivariate analysis, 6-month TRS (HR, 2.84; 95% CI, 1.44-6.91,p = 0.02) was significantly associated with increased risk of CAV onset. The 12- and 24-month rejection scores were not risk factors for the onset of CAV. By Kaplan-Meier analysis, 6-month TRS exceeding 0.3 was associated with a significantly shorter time to CAV onset (p = 0.018). There was direct correlation (r = 0.44, p = 0.012) between TRS at 6 months and the percentage of necrotic core demonstrated by VH-IVUS at 24 months. Conclusion: Recurrent cellular rejection has a cumulative effect on the onset of CAV. The mechanism may be due to increased inflammation resulting in increased plaque burden suggesting a relationship between the immune basis of cellular rejection and CAV. J Heart Lung Transplant 2009;28:320-7. Copyright (C) 2009 by the International Society for Heart and Lung Transplantation.
引用
收藏
页码:320 / 327
页数:8
相关论文
共 58 条
[1]   Morphologic observations in the epicardial coronary arteries and their surroundings late after cardiac transplantation (allograft vascular disease) [J].
Arbustini, E ;
Roberts, WC .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (07) :814-820
[2]   Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy [J].
Bae, Jang-Ho ;
Rihal, Charanjit S. ;
Edwards, Brooks S. ;
Kushwaha, Sudhir S. ;
Mathew, Verghese ;
Prasad, Abhiram ;
Holmes, David R., Jr. ;
Lerman, Amir .
TRANSPLANTATION, 2006, 82 (08) :1108-1111
[3]   The revised ISHLT heart biopsy grading scale [J].
Billingham, M ;
Kobashigawa, JA .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (11) :1709-1709
[4]  
BILLINGHAM ME, 1992, J HEART LUNG TRANSPL, V11, pS38
[5]  
BILLINGHAM ME, 1987, TRANSPLANT P, V19, P19
[6]   Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease [J].
Brunner-La Rocca, HP ;
Schneider, J ;
Künzli, A ;
Turina, M ;
Kiowski, W .
TRANSPLANTATION, 1998, 65 (04) :538-543
[7]   Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: Multivariate risk factor analysis and role of immunosuppression [J].
Caforio, ALP ;
Tona, F ;
Fortina, AB ;
Angelini, A ;
Piaserico, S ;
Gambino, A ;
Feltrin, G ;
Ramondo, A ;
Valente, M ;
Iliceto, S ;
Thiene, G ;
Gerosa, G .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (06) :962-970
[8]   Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab - Results of the Diabetes Abciximab SteNT Evaluation (DANTE) randomized trial [J].
Chaves, AJ ;
Sousa, AGMR ;
Mattos, LA ;
Abizaid, A ;
Staico, R ;
Feres, F ;
Centemero, M ;
Tanajura, LF ;
Abizaid, A ;
Pinto, I ;
Maldonado, G ;
Seixas, A ;
Costa, MA ;
Paes, A ;
Mintz, GS ;
Sousa, JE .
CIRCULATION, 2004, 109 (07) :861-866
[9]  
Costanzo MR, 1998, J HEART LUNG TRANSPL, V17, P744
[10]   Association between acute rejection and cardiac allograft vasculopathy [J].
Dandel, M ;
Hummel, M ;
Wellnhofer, E ;
Kapell, S ;
Lehmkuhl, HB ;
Hetzer, R .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2003, 22 (09) :1064-1065